These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9724812)

  • 1. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma.
    Turski L; Huth A; Sheardown M; McDonald F; Neuhaus R; Schneider HH; Dirnagl U; Wiegand F; Jacobsen P; Ottow E
    Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10960-5. PubMed ID: 9724812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphonate quinoxalinedione AMPA antagonists.
    Turski L; Schneider HH; Neuhaus R; McDonald F; Jones GH; Löfberg B; Schweinfurth H; Huth A; Krüger M; Ottow E
    Restor Neurol Neurosci; 2000; 17(1):45-59. PubMed ID: 11490077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotine-induced dopamine release in the nucleus accumbens is inhibited by the novel AMPA antagonist ZK200775 and the NMDA antagonist CGP39551.
    Kosowski AR; Cebers G; Cebere A; Swanhagen AC; Liljequist S
    Psychopharmacology (Berl); 2004 Aug; 175(1):114-23. PubMed ID: 15088078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
    Desos P; Lepagnol JM; Morain P; Lestage P; Cordi AA
    J Med Chem; 1996 Jan; 39(1):197-206. PubMed ID: 8568808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effect of YM90K, an AMPA-receptor antagonist, against delayed neuronal death induced by transient global cerebral ischemia in gerbils and rats.
    Kawasaki-Yatsugi S; Yatsugi S; Koshiya K; Shimizu-Sasamata M
    Jpn J Pharmacol; 1997 Jul; 74(3):253-60. PubMed ID: 9268085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YM872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist.
    Takahashi M; Kohara A; Shishikura J; Kawasaki-Yatsugi S; Ni JW; Yatsugi S; Sakamoto S; Okada M; Shimizu-Sasamata M; Yamaguchi T
    CNS Drug Rev; 2002; 8(4):337-52. PubMed ID: 12481190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists?
    Buchan AM; Lesiuk H; Barnes KA; Li H; Huang ZG; Smith KE; Xue D
    Stroke; 1993 Dec; 24(12 Suppl):I148-52. PubMed ID: 7504338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMPA antagonist ZK200775 in patients with acute ischemic stroke: possible glial cell toxicity detected by monitoring of S-100B serum levels.
    Elting JW; Sulter GA; Kaste M; Lees KR; Diener HC; Hommel M; Versavel M; Teelken AW; De Keyser J
    Stroke; 2002 Dec; 33(12):2813-8. PubMed ID: 12468775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia.
    Gill R
    Cerebrovasc Brain Metab Rev; 1994; 6(3):225-56. PubMed ID: 7529037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds.
    Ohmori J; Shimizu-Sasamata M; Okada M; Sakamoto S
    J Med Chem; 1996 Sep; 39(20):3971-9. PubMed ID: 8831762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischaemic damage after middle cerebral artery occlusion in rats.
    Kawasaki-Yatsugi S; Shimizu-Sasamata M; Yatsugi S; Yamaguchi T
    J Pharm Pharmacol; 1998 Aug; 50(8):891-8. PubMed ID: 9751454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPA receptor antagonist, YM90K, reduces infarct volume in thrombotic distal middle cerebral artery occlusion in spontaneously hypertensive rats.
    Yao H; Ibayashi S; Nakane H; Cai H; Uchimura H; Fujishima M
    Brain Res; 1997 Apr; 753(1):80-5. PubMed ID: 9125434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
    Shimizu-Sasamata M; Kawasaki-Yatsugi S; Okada M; Sakamoto S; Yatsugi S; Togami J; Hatanaka K; Ohmori J; Koshiya K; Usuda S; Murase K
    J Pharmacol Exp Ther; 1996 Jan; 276(1):84-92. PubMed ID: 8558460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kynurenic acid analogues with improved affinity and selectivity for the glycine site on the N-methyl-D-aspartate receptor from rat brain.
    Foster AC; Kemp JA; Leeson PD; Grimwood S; Donald AE; Marshall GR; Priestley T; Smith JD; Carling RW
    Mol Pharmacol; 1992 May; 41(5):914-22. PubMed ID: 1375317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effect of NMDA receptor glycine recognition site antagonism persists when brain temperature is controlled.
    Takaoka S; Bart RD; Pearlstein R; Brinkhous A; Warner DS
    J Cereb Blood Flow Metab; 1997 Feb; 17(2):161-7. PubMed ID: 9040495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model.
    Kawasaki-Yatsugi S; Ichiki C; Yatsugi S; Takahashi M; Shimizu-Sasamata M; Yamaguchi T; Minematsu K
    Neuropharmacology; 2000 Jan; 39(2):211-7. PubMed ID: 10670416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors.
    Cai SX; Huang JC; Espitia SA; Tran M; Ilyin VI; Hawkinson JE; Woodward RM; Weber E; Keana JF
    J Med Chem; 1997 Oct; 40(22):3679-86. PubMed ID: 9357535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction.
    Xue D; Huang ZG; Barnes K; Lesiuk HJ; Smith KE; Buchan AM
    J Cereb Blood Flow Metab; 1994 Mar; 14(2):251-61. PubMed ID: 7509339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
    Graham SH; Chen J; Lan JQ; Simon RP
    J Pharmacol Exp Ther; 1996 Jan; 276(1):1-4. PubMed ID: 8558416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.